• No results found

ULTRASONIC INVESTIGATION OF AQUEOUS DEXTRAN AT DIFFERENT TEMPERATURES AND FREQUENCIES

N/A
N/A
Protected

Academic year: 2020

Share "ULTRASONIC INVESTIGATION OF AQUEOUS DEXTRAN AT DIFFERENT TEMPERATURES AND FREQUENCIES"

Copied!
7
0
0

Loading.... (view fulltext now)

Full text

Figure

Table 1: The experimental values of density (ρ) and viscosity (η) at 303K, 308K, 313K and 318K of aqueous solution of Dextran
Figure 1 contains the plot of ultrasonic velocity versus molar concentration. It is observed that ultrasonic velocity increases with increase in temperature indicating association in the constituent
Fig. 3: Variation of adiabatic compressibility with  temperature.
Fig. 7: Variation of intermolecular free length with  temperature.
+2

References

Related documents

In [5], Cameron and Storvick evaluated the Feynman integral of the first variation of certain functionals on Wiener space and in [13], Park, Skoug, and Storvick examined

EstanyolPuigdomenech2405 4 pm Genetic, molecular and cellular approaches to the analysis of maize embryo development MATILDE JOS? ESTANYOL, IGNACIO L?PEZ RIBERA, MIRIAM BASTIDA,

That one (Plate VIII, fig. 66) shows that the structure of the pachy- tene chromosome of Lilium pollen mother cells is not very different from the structure of the

Furthermore, the fact that rDUNE values are on average higher in the marl region compared to schist catchments is physically reasonable, considering the fact that soil cracks and

In particular, the dimension estimates and the grouping of streamflow time series (Fig. 4) clearly show that: (1) the dimensionality concept captures the complex- ity of

These findings suggested that CS-6 inhibit cell growth and induce cellular senescence in A549 cells by down regulating cell growth and cellular senescence associated Hsp90

After 2 wk of treatment, adipose cell size and basal glucose transport and metabolism were unaltered, but insulin-stimulated transport and glucose metabolism were increased two-

Final results of bevacizumab (BV) plus capecitabine plus oxaliplatin (XELOX) as first-line therapy in Japanese patients (pts) with metastatic colorectal cancer (MCRC). Ichante